The HealthTech Signal
Chai Discovery triples its valuation as pharma buys into AI-designed molecules
Chai Discovery triples its valuation as pharma buys into AI-designed molecules
Dr. Dereck Mush, MD, MBA
Nimbus Therapeutics
Structure-based drug discovery and AI-enabled chemistry for small-molecule medicines.
What they do
Nimbus Therapeutics announced first-in-human dosing of NDI-225673 on November 10, 2026. The investigational oral compound selectively targets salt-inducible kinase 2 (SIK2) for potential treatment of immune-mediated inflammatory diseases. The Phase 1 study evaluates safety, tolerability, pharmacokinetics and pharmacodynamics in healthy volunteers using single and multiple ascending doses. First dosing is an early clinical development milestone, not proof of clinical efficacy or an approved treatment.
The record
- Vertical
- Biotech & Drug Discovery
- Sub-segment
- Computational small-molecule discovery
- Product type
- Platform software
- Stage
- Headquarters
- Not disclosed
- Region
- Founded
- Not disclosed
- Total funding
- Undisclosed
Also in Biotech & Drug Discovery
Related on The Signal
Dr. Dereck Mush, MD, MBA
Renting the Molecule Factory: Pierre Fabre, XtalPi and Mid-Sized Pharma's AI Bet
Dr. Dereck Mush, MD, MBA
AI is moving upstream, from molecule design into disease target identification itself
Dr. Dereck Mush, MD, MBA
What Pharma Is Buying From AI Drug Discovery: Inside AstraZeneca’s insitro Deal
Dr. Dereck Mush, MD, MBA